Literature DB >> 8585750

In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis.

J M Blondeau1, Y Yaschuk.   

Abstract

Moderately penicillin-resistant Neisseria meningitidis was responsible for an outbreak of meningococcal disease in Saskatoon, Saskatchewan, Canada in 1993. We tested fully susceptible and moderately resistant strains of N. meningitidis against ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, penicillin, and rifampin. Eighteen percent of the isolates were moderately resistant to penicillin (MIC > or = 0.06 microgram/ml) whereas susceptibility was 100% for the other agents tested.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585750      PMCID: PMC162989          DOI: 10.1128/AAC.39.11.2577

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Penicillin resistance in Neisseria meningitidis.

Authors:  G Riley; S Brown; C Krishnan
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

2.  Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis.

Authors:  M P Pugsley; D L Dworzack; E A Horowitz; T A Cuevas; W E Sanders; C C Sanders
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

3.  Meningococcal disease in Malawi: studies on the genetic relatedness of the bacteria.

Authors:  B Bellete; L E Cuevas; P Kazembe; G Mughogho; D Sunderland; C A Hart
Journal:  Ann Trop Med Parasitol       Date:  1994-02

4.  Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland.

Authors:  O V Renkonen; A Sivonen; R Visakorpi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  Isolation of Neisseria meningitidis strains with increase of penicillin minimal inhibitory concentrations.

Authors:  J A Sáez-Nieto; D Fontanals; J Garcia de Jalon; V Martinez de Artola; P Peña; M A Morera; R Verdaguer; I Sanfeliu; C Belio-Blasco; J L Perez-Saenz
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

Review 6.  Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989).

Authors:  J A Sáez-Nieto; R Lujan; S Berrón; J Campos; M Viñas; C Fusté; J A Vazquez; Q Y Zhang; L D Bowler; J V Martinez-Suarez
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

7.  Antibiotic sensitivities of Neisseria meningitidis isolates from patients and carriers in Greece.

Authors:  G Tzanakaki; C C Blackwell; J Kremastinou; C Kallergi; G Kouppari; D M Weir
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

8.  Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group.

Authors:  L A Jackson; F C Tenover; C Baker; B D Plikaytis; M W Reeves; S A Stocker; R E Weaver; J D Wenger
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

9.  E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.

Authors:  J H Hughes; D J Biedenbach; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

10.  Neisseria meningitidis with decreased susceptibility to penicillin in Saskatchewan, Canada.

Authors:  J M Blondeau; F E Ashton; M Isaacson; Y Yaschuck; C Anderson; G Ducasse
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

  10 in total
  5 in total

1.  Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older.

Authors: 
Journal:  Paediatr Child Health       Date:  2001-03       Impact factor: 2.253

2.  [Standardization of the Neisseria meningitidis antibiogram. Detection of strains relatively resistant to penicillin].

Authors:  P Nicolas; J D Cavallo; R Fabre; G Martet
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 3.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.